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Abstract
The analgesic activity of acetyl-L-carnitine (ALCAR) in neuropathic pain is well established. By contrast, its potential efficacy
in the relief of acute pain has not been reported. The antinociceptive effect of ALCAR was, therefore, examined in the mouse hot-
plate and abdominal constriction tests, and in the rat paw-pressure test. ALCAR (100 mg kg1 s.c. twice daily for seven days)
produced an increase of the pain threshold in both mice and rats. ALCAR was also able to reverse hyperalgesia induced by kainic
acid and NMDA administration in the mouse hot-plate test. The antinociception produced by ALCAR was prevented by the unselec-
tive muscarinic antagonist atropine, the M1 selective antagonists pirenzepine and S-(-)-ET126, and by the choline uptake inhibitor
hemicholinium-3 (HC-3). By contrast the analgesic effect of ALCAR was not prevented by the opioid antagonist naloxone, the
GABAB antagonist CGP 35348, the monoamine synthesis inhibitor (a)-methyl-p-tyrosine, and the Gi-protein inactivator pertussis
toxin. Moreover, ALCAR antinociception was abolished by pretreament with an antisense oligonucleotide (aODN) against the M1
receptor subtype, administered at the dose of 2 nmol per single i.c.v injection. On the basis of the above data, it can be postulated
that ALCAR exerted an antinociceptive effect mediated by a central indirect cholinergic mechanism. In the antinociceptive dose-
range, ALCAR did not impair mouse performance evaluated by the rota-rod and hole-board tests.
 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Acetyl-L-carnitine (γ-trimethyl-β-acetylbutyrobetaine;
ALCAR), the acetyl ester of carnitine, is a small water-
soluble molecule naturally present in the central nervous
system. ALCAR exerts a neuroprotective effect by
increasing glutathione and by decreasing the concen-
tration of malondialdehyde (Fariello et al., 1987), pro-
moting nerve growth factor receptor synthesis and
increasing its levels in the hippocampus (Taglialatela et
al., 1991, 1992).
Several studies have indicated that ALCAR is
involved in different aspects of neuronal activity. It has
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been demonstrated to improve cognitive deficits in some
experimental paradigms (Pettegrew et al., 1995;
Dell’Anna et al., 1997), to modify the cerebral electrical
activity (Mancia et al., 1990); and to induce an antide-
pressant-like effect (Pulvirenti et al., 1990). Furthermore,
ALCAR modulates the release of various neurotransmit-
ters such as dopamine (Harsing et al., 1992), excitatory
amino acids, taurine (Toth et al., 1993), acetylcholine
(Imperato et al., 1989), and GABA (Fariello et al., 1988).
ALCAR has also been demonstrated to be signifi-
cantly effective in reducing neuropathic pain, a condition
characterised by spontaneous pain, allodynia and hyper-
algesia caused by traumatic injury, diabetes, and viral
infections. Intramuscular chronic treatment with
ALCAR significantly improves the outcome of painful
neuropathies or radiculopathies (Onofrj et al., 1995). A
beneficial effect of ALCAR has been reported in the
treatment of symptomatic diabetic neuropathy (Quatraro
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et al., 1995) and in the treatment of pain in distal sym-
metrical polyneuropathy related to HIV infection
(Scarpini et al., 1997). However, the mechanism under-
lying the analgesic effect of ALCAR is still obscure.
By contrast, its potential efficacy in the relief of acute
pain has not been reported. On these bases, the aim of
the present study was to first investigate the analgesic
properties of ALCAR in animal models of acute pain
by using different nociceptive stimuli, such as thermal,
chemical and mechanical. We also investigated the
receptor subtypes involved in the increase of pain thres-
hold induced by ALCAR to elucidate its mechanism
of action.
In order to exclude that the effects produced by
ALCAR treatment were due to the induction of side




Maple Swiss albino mice (23–25 g) and Wistar rats
(150–200 g) from the Morini (San Polo d’Enza, Italy)
breeding farm were used. Fifteen mice or five rats were
housed per cage (26 × 41 cm). The cages were placed
in the experimental room 24 h before the test for
acclimatisation. The animals were fed a standard labora-
tory diet and tap water ad libitum and kept at 23 ± 1°C
with a 12 h light/dark cycle, light on at 7 a.m. Each
animal was used only once and was killed immediately
after the end of the experiment by exposure to diethyl
ether. All experiments were carried out in accordance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC) for experimental animal
care. All efforts were made to minimise animal suffer-
ing, and to reduce the number of animals used.
2.2. Intracerebroventricular injection technique
Intracerebroventricular (i.c.v.) administration was per-
formed under ether anaesthesia, according to the method
described by Haley and McCormick (1957). Briefly, dur-
ing anaesthesia, mice were grasped firmly by the loose
skin behind the head. A 0.4 mm external diameter, hypo-
dermic needle attached to a 10 µl syringe was inserted
perpendicularly through the skull and no more than 2
mm into the brain of the mouse, where 5 µl were then
administered. The injection site was 1 mm to the right
or left from the midpoint on a line drawn through to the
anterior base of the ears. Injections were performed into
the right or left ventricle randomly. To ascertain that the
drugs were administered exactly into the cerebral ven-
tricle, some mice (20%) were injected with 5 µl of
diluted 1:10 India ink and their brains examined macro-
scopically after sectioning. The accuracy of the injection
technique was evaluated and the percentage of correct
injections was 95.
2.3. Intrathecal injection technique
Intrathecal injections were performed under ether
anaesthesia as described by Hylden and Wilcox (1980)
in which the mouse was gently restrained and a 30-
gauge, 1/2-inch needle mated to a 50 µl Hamilton syr-
inge was inserted between L5 and L6 of the mouse spi-
nal column. A volume of 5 µl was used for i.t. injection.
2.4. Hot-plate test
The method adopted was described by O’Callaghan
and Holzman (1975). Mice were placed inside a stainless
steel container, thermostatically set at 52.5 ± 0.1°C in a
precision water-bath from KW Mechanical Workshop,
Sienna, Italy. Reaction times (s), were measured with a
stop-watch before and at regular intervals up to a
maximum of 120 min after treatment. The endpoint used
was the licking of the fore or hind paws. Before pretreat-
ing animals with ALCAR, a pretest was performed:
those mice scoring below 12 and over 18 s in the pretest
were rejected (30%). An arbitrary cut-off time of 45 s
was adopted.
2.5. Abdominal constriction test
Mice were injected i.p. with a 0.6% solution of acetic
acid (10 ml kg1), according to Koster et al. (1959). The
number of stretching movements was counted for 10
min, starting 5 min after acetic acid injection.
2.6. Paw pressure test
The nociceptive threshold in the rat was determined
with an analgesimeter (Ugo Basile, Varese, Italy),
according to the method described by Leighton et al.
(1988). Threshold pressure was measured before and 15,
30, 45 and 60 min after treatment. Before pretreating
animals with ALCAR a pretest was performed: rats scor-
ing below 30 g or over 85 g were rejected (25%). An
arbitrary cut-off value of 250 g was adopted.
2.7. Hole-board test
The hole board test consisted of a 40 cm square plane
with 16 flush mounted cylindrical holes (3 cm diameter)
distributed 4 × 4 in an equidistant, grid-like manner.
Mice were placed on the centre of the board one by one
and allowed to move about freely for a period of 10 min
each. Two electric eyes, crossing the plane from mid-
point to mid-point of opposite sides, thus dividing the
plane into four equal quadrants, automatically signalled
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the movement of the animal (counts in 5 min) on the
surface of the plane (locomotor activity). Miniature
photoelectric cells, in each of the 16 holes, recorded
(counts in 5 min) the exploration of the holes
(exploratory activity) by the mice.
2.8. Rota-rod test
The apparatus consisted of a base platform and a rotat-
ing rod with a diameter of 3 cm and a non-slippery sur-
face. The rod was placed at a height of 15 cm from the
base. The rod, 30 cm in length, was divided into five
equal sections by six disks. Thus, up to five mice were
tested simultaneously on the apparatus, with a rod-rotat-
ing speed of 16 r.p.m. The integrity of motor coordi-
nation was assessed on the basis of the number of falls
from the rod in 30 s according to Vaught et al. (1985).
Before pretreating animals with ALCAR a pretest was
performed: mice scoring less than three and more than
six falls in the pretest were rejected (20%). The perform-
ance time was measured before (pretest) and 15, 30 and
45 min after s.c. treatment.
2.9. Antisense oligonucleotides
Low cell permeability and the high degradation of
natural phosphodiester oligomers are considerable draw-
backs in the application of aODNs both in vitro and in
vivo. To overcome these drawbacks, phosphorothioate-
capped phosphorodiester oligonucleotides were used.
The above-mentioned compounds are a class of ODN
derivatives shown to maintain more stable and effective
concentrations in the brain when compared with their
unmodified counterpart (Whitesell et al., 1993). Phos-
phodiester oligonucleotides (ODNs) protected by ter-
minal phosphorothioate double substitution (capped
ODNs) against possible exonuclease-mediated degra-
dation were purchased from Genosys (Cambridge,
England) and purified by high-performance liquid chro-
matography (HPLC). The 18-mer antisense ODN
(aODN) 5’-CAC TGA GGT GTT CAT TGC-3’
(phosphorothioate residues are underlined) complemen-
tary to the residues 112–129 of the published mouse M1
cDNA sequence (Shapiro et al., 1988) and the 18-mer
fully degenerated ODN (dODN) 5’-NNN NNN NNN
NNN NNN NNN-3’ (where N is G, or C, or A, or T
and phosphorothioate residues are underlined) were
vehiculated intracellularly by an artificial cationic lipid
(DOTAP, Boehringer-Mannheim, Germany) to enhance
both uptake and stability. aODN or dODN (100–400
µM) were preincubated at 37°C for 30 min with 13 µM
DOTAP, sterilised through a 0.2 µm filter and supplied
to mice by i.c.v. injection of a 5 µl solution as described
in the next section.
The accession number of the cDNA sequence for the
mouse muscarinic receptor subtype reported in this paper
(M1) is J04192.
2.10. Drugs
The following drugs were used: Acetyl-L-carnitine,
Acetyl-D-carnitine, L-carnitine, D-carnitine (Sigma-Tau,
Italy); hemicholinium-3 hydrobromide (HC-3), piren-
zepine dihydrochloride, naloxone hydrochloride, per-
tussis toxin (RBI); atropine sulfate, a-methyl p-tyrosine
methyl ester hydrochloride, kainic acid, N-metyl-D-
aspartic acid (NMDA), DOTAP (Sigma); CGP 35348
(Ciba Geigy); S-(-)-ET 126 (S-(-)-a-
(hydroxymethyl)benzene-acetic acid 1-methyl-4-piperid-
inyl ester) prepared in the Department of Pharmaceutical
Sciences of Florence; D-amphetamine hydrochloride (De
Angeli). All drugs were dissolved in isotonic (NaCl
0.9%) saline solution immediately before use, except for
pertussis toxin which was dissolved in a water solution
containing 0.01 M sodium phosphate buffer, pH  7.0,
with 0.05 M sodium chloride. Drug concentrations were
prepared in such a way that the necessary dose could be
administered in a volume of 10 ml kg1 by s.c. or i.p.
injection or 5 µl per mouse by i.c.v. or i.t. injection.
2.11. Statistical analysis
All experimental results are given as the
mean ± S.E.M. Analysis of variance (ANOVA), fol-
lowed by Fisher’s Protected Least Significant Difference
(PLSD) procedure for post-hoc comparison, was used to
verify significance between two means. Data were ana-
lysed with the StatView software for the Macintosh
(1992). P values of less than 0.05 were considered sig-
nificant.
3. Results
3.1. Antinociceptive activity of ALCAR
ALCAR, as shown in Fig. 1, increased the pain thres-
hold in the mouse hot-plate test after s.c. administration
(100–200 mg kg1) twice daily for seven days (panel b).
After 14 day-treatment, the licking latency values
recorded in the ALCAR-treated group were similar to
those measured after 7-day treatment (data not shown).
The analgesic effect of ALCAR persisted up to seven
days after the end of the 7-day treatment. The increase
of the pain threshold induced by ALCAR disappeared
21 days after the end of the treatment (data not shown).
Acute administration of ALCAR (100–200 mg kg1 s.c.)
was not able to produce any statistically significant
increase of the pain threshold (Fig. 1, panel a). Similarly,
the dose of 30 mg kg1 s.c. was devoid of any effect
after acute (Fig. 1, panel a) or subchronic (Fig. 1,
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Fig. 1. Dose-response curves of ALCAR after acute (panel a) and
subchronic treatment (twice daily for 7 days: panel b) in the hot-plate
test. The doses are expressed as mg kg1 s.c.. The licking latency
values were recorded every 15 min up to 120 min from the beginning
of the test. In panel a) ALCAR was injected at time 0; in panel b)
the last injection of ALCAR was performed 24 h after the last injec-
tion. Vertical lines give s.e. mean. Each point is the mean of at least
12 mice. ∗P  0.01 in comparison with the respective saline controls.
panel b) treatment. The administration of acetyl-D-carni-
tine, L-carnitine and D-carnitine, twice daily for seven
days at the dose of 100 mg kg1 s.c., did not produce
any analgesic effect in the hot-plate (data not shown).
ALCAR was able to induce antinociception also in the
mouse abdominal constriction test. After 14-day treat-
ment at the dose of 100 mg kg1 s.c., ALCAR induced
antinociception (Fig. 2), whereas, after 7-day treatment,
the investigated compound produced a reduction of the
number of abdominal constrictions that did not reach
statistical significance (Fig. 2). A lower dose of ALCAR
(30 mg kg1 s.c.) was devoid of any effect regardless
of the administration procedure employed (Fig. 2). Simi-
larly to the results obtained in the mouse hot-plate test,
ALCAR was ineffective after acute administration in the
abdominal constriction test (Fig. 2). Pretreatment with
acetyl-D-carnitine, L-carnitine and D-carnitine, twice
daily for 14 days at the dose of 100 mg kg1 s.c., did
not produce any analgesic effect in comparison with
ALCAR (Fig. 2).
In the paw pressure test ALCAR, administered i.p. at
the dose of 100 mg kg1 s.c. in the rat, induced antinoc-
iception after subchronic treatment (twice daily for seven
days) (data not shown).
ALCAR also had antihyperalgesic activity. At 100 mg
kg1 s.c. it reversed hyperalgesia induced by adminis-
tration of kainic acid (20 mg kg1 i.p.) or NMDA (1.64
µg per mouse i.t.) in the mouse hot-plate test after subch-
ronic treatment (twice daily for seven days). After acute
treatment ALCAR was devoid of any effect (Fig. 3). No
significant antihyperalgesic effect was observed at 30 mg
kg1 s.c. (Fig. 3).
3.2. Antagonism of ALCAR antinociception
In the mouse hot-plate test, the antinociceptive effect
of ALCAR (100 mg kg1 s.c., twice daily for seven
days) was antagonised by atropine (5 mg kg1 i.p.), pir-
enzepine (0.1 µg per mouse i.c.v.), S-(-)-ET126 (0.1 µg
per mouse i.c.v.), and hemicolinium-3 (1 µg per mouse
i.c.v.) (Fig. 4). By contrast, naloxone (1 mg kg1 i.p.),
CGP-35348 (100 mg kg1 i.p.), a-methyl-p-tyrosine
(200 mg kg1 i.p.), and pertussis toxin (0.25 µg per
mouse i.c.v.) did not prevent ALCAR antinociception
(Fig. 4).
All antagonists were injected 15 min before the test,
with the exception of CGP 35348, a-methyl-p-tyrosine,
hemicholinium-3 and pertussis toxin injected respect-
ively 5 min, 1 h, 5 h and 11 days before the test.
The doses and administration schedules of the above-
mentioned antagonists were selected for preventing anti-
nociception induced by the corresponding agonists with-
out modifying the increase of pain threshold induced by
activation of other neurotransmission systems (Bartolini
et al., 1987; Malcangio et al., 1991; Ghelardini et al.,
1992; Ghelardini et al., 1996). Furthermore, previous
results indicated that an 11-day latency was required to
abolish analgesia mediated through activation of the Gi
protein-mediated system.
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Fig. 2. Effect of ALCAR, L-carnitine, D-carnitine and acetyl-D-carnitine in mouse abdominal constriction test. Each column represents the mean
of at least 12 mice. Nociceptive response was recorded 30 min (acute treatment) and 24 h (suchronic treatment) after the last s.c. injection of
ALCAR and structurally related compounds. ∗P  0.01 in comparison with saline-treated mice.
Fig. 3. Effect of ALCAR on hyperalgesia induced by kainic acid (20
mg kg1 i.p.) and NMDA (1.64 µg per mouse i.t.) in mouse hot-plate
test. Nociceptive responses were recorded 30 min (acute treatment)
and 24 h (subchronic treatment) after the last ALCAR injection. Kainic
acid and NMDA were administered respectively 48 h and 15 min
before ALCAR administration. ∗P  0.01 in comparison with kainic
acid/NMDA-treated mice. Each column represents the mean of at least
8 mice.
3.3. Effect of anti-M1 treatment on ALCAR
antinociception
Mice were pretreated with a single i.c.v. injection of
antisense ODN (aODN) to the M1 gene, degenerate
ODN (dODN), or vehicle, on days 1, 4 and 7. The effect
of aODN pretreatment on ALCAR (100 mg kg1 s.c.,
twice daily for seven days) induced antinociception was
then evaluated in the mouse hot-plate test. aODN, at the
dose of 2 nmol per i.c.v. injection, prevented the
ALCAR-induced increase of pain threshold (Fig. 4).
This antagonistic effect was detected 24 h after the last
i.c.v. injection.
Seven days after the end of the aODN treatment,
ALCAR induced an antinociceptive effect of the same
intensity in aODN-, dODN- and vehicle-treated mice,
Fig. 4. Effect of atropine, hemicholinium-3 (HC-3), pirenzepine, S-
(-)-ET-126, aODN to M1 gene, naloxone, CGP-35348, a-methyl-p-
tyrosine (a-M-p-T) and pertussis toxin (PTX) on antinociception
induced by ALCAR (100 mg kg1 s.c. twice daily × 7 days) in mouse
hot-plate test. All antagonists were injected 15 min before the test, with
the exception of CGP-35348, a-methyl-p-tyrosine, hemicholinium-3
and pertussis toxin injected respectively 5 min, 1 h, 5 h and 11 days
before test. Each value represents the mean of at least 10 mice.
Nociceptive responses were recorded 24 h after the last s.c. injection
of ALCAR. Mice were i.c.v. injected with aODN at the dose of 2.0
nmol per single i.c.v. injection on days 1, 4 and 7 and the hot plate
test was peformed 24 h after the last i.c.v. injection of aODN. Vertical
lines give S.E.M. ∗P  0.01 in comparison with ALCAR treated-
mice.
indicating the loss of antagonistic activity by the anti-
M1 aODN (data not shown). The aODN, when injected
alone, did not alter the pain threshold in mice, showing
a lack of any hyperalgesic effect. Pretreatment with
dODN did not modify ALCAR-induced antinociception
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in comparison with mice injected with vehicle (data
not shown).
The dose and administration schedule for aODN was
ideal for selectively preventing analgesia induced by
direct and indirect muscarinic cholinomimetics
(Ghelardini et al., 2000).
3.4. Effect of ALCAR on mouse behaviour
The spontaneous motility and exploratory behaviour
of mice were not modified by treatment with ALCAR
(100 mg kg1 s.c. twice daily for 14 days) as revealed by
the hole-board test (Table 1). In the same experimental
conditions, D-amphetamine (2 mg kg1 s.c.), used as the
reference drug, increased both parameters evaluated.
The motor coordination of mice treated with ALCAR
was evaluated by using the rota-rod test (Table 1). The
rota-rod performance of mice treated with ALCAR at
the dose of 100 mg kg1 s.c. twice daily for seven (data
not shown) or 14 days was not impaired in comparison
with controls (Table 1). The number of falls by control
animals progressively decreased at every measurement
since the mice learnt how to balance on the rotating rod.
4. Discussion
ALCAR was able to induce antinociception in mice
and rats. The increase of the pain threshold was elicited
regardless of which noxious stimulus was used: thermal
(hot-plate test), chemical (abdominal constriction test)
and mechanical (paw pressure test). ALCAR was also
able to reverse hyperalgesia induced by kainic acid and
NMDA administration, in the mouse hot-plate test.
ALCAR antinociception was obtained without producing
Table 1
Lack of effect of ALCAR (100 mg kg1 s.c. twice daily for 14 days) in mouse hole-board (panel A) in comparison with D-amphetamine (2 mg
kg1 s.c.), and in Rota-rod test (panel B)a
Panel A
Locomotory activity Explorative activity
Treatment Number of mice Number of movements Number of explorations
Saline 7 59.4±7.7 21.3±5.6
ALCAR 10 52.3±6.5 24.0±5.1
D-Amphetamine 10 82.3±4.8∗ 34.1±3.9∗
Panel B
Rota-rod—Falls in 30 s
Treatment Number of mice Before treament After treatment
15 min 30 min 45 min
Saline 5 4.2±0.4 3.1±0.4 2.2±0.2 1.6±0.3
ALCAR 5 3.9±0.5 2.9±0.3 1.7±0.4 1.0±0.3
a Rota rod and hole-board test was performed 30 min after the last ALCAR administration. Amphetamine was injected 15 min before test.
∗P0.01 in comparison with saline controls.
any visible modification of animal gross behaviour.
Moreover, ALCAR treated mice showed a complete
integrity of motor coordination on the rota-rod test, nor-
mal spontaneous motility, as well as exploratory behav-
iour, as revealed by the hole-board test.
The antinociceptive effect of ALCAR did not reach
statistical significance after acute administration. After
7-day treatment (twice daily) there was an increase of
the pain threshold. The only exception was the abdomi-
nal constriction test, in which the ALCAR analgesia was
significant only after 14-day treatment. The hot-plate,
paw pressure and abdominal constriction tests involve
three different nociceptive stimuli. The detection of the
analgesic effect of ALCAR after long term treatment is
in agreement with results obtained in clinical studies in
which ALCAR was used to relieve neuropathic pain
(Onofrj et al., 1995; Quatraro et al., 1995; Scarpini et
al., 1997). The enhancement of the pain threshold
induced by ALCAR was still present seven days after
the end of the subchronic treatment. This long-term anal-
gesic effect, together with the complete absence of
induction of any side effect after 14-day treatment, con-
fers to ALCAR an advantageous pharmacological pro-
file.
The analgesia induced by ALCAR is stereospecific
since acetyl-D-carnitine is devoid of any antinociceptive
activity. Moreover, related compounds such L-carnitine
and D-carnitine did not induce any increase of
response threshold.
ALCAR antinociception was found to be dependent
on central cholinergic activation since it was prevented
by the non-selective muscarinic antagonist atropine, the
selective M1-antagonists pirenzepine and S-(-)-ET-126,
the ACh depletor hemicolinium-3 and an aODN to the
M1 receptor subtype. The aODN treatment induces a
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transient prevention of muscarinic antinociception since
the inhibition of the ALCAR effect disappeared seven
days after the last i.c.v. injection of the aODN. This
return to normal sensitivity to analgesic treatments
implies both the total reversal of aODN-induced specific
inhibition of M1 gene expression and a lack of damage
or toxicity associated with aODN treatment.
Cholinergic antinociception in mice and rats is
mediated by M1 receptor stimulation (Bartolini et al.,
1992; Iwamoto and Marion, 1993). Furthermore, chol-
inergic antinociception induced both directly, through
muscarinic agonists, and indirectly, by enhancing ACh
extracellular levels through cholinesterase inhibitors, is
prevented by i.c.v. administration of an antisense to the
M1 gene coding for the mouse M1 receptor. The efficacy
and selectivity of the aODN employed towards M1
receptor was previously demonstrated by us (Ghelardini
et al., 2000).
The activation of the muscarinic system by ALCAR
in the induction of its pharmacological effects has been
reported. Cortical application of ALCAR exerted an
excitatory action on cells excited by acetylcholine and
changed the components of the visual evoked potentials
in rats by a mechanism that was prevented by atropine
(Onofrj et al., 1983). The microiontophoretic application
of ALCAR increased the firing rate of single cholinocep-
tive neurons of the somatosensory cortex in rats in an
atropine-sensitive manner (Janiri et al., 1991). ALCAR
has also be reported to produce atropine-sensitive mus-
carinic effects induced by application of ACh such as
increase of salivation, reduction of pupil diameter and
blood pressure (Blum et al., 1971).
Taking into account that HC-3, pirenzepine and S-(-)
-ET126 were able to antagonise ALCAR antinociception
after i.c.v. injection, this indicates that the analgesic site
of action of ALCAR is localised in the CNS.
A presynaptic mechanism facilitating cholinergic
transmission is involved in ALCAR antinociception as
revealed by the antagonism by HC-3. A postsynaptic
mechanism of action can be ruled out since, as reported
by Bartolini et al. (1987, 1992), HC-3 was not able to
antagonise antinociception induced by agonists of post-
synaptic muscarinic receptors such as oxotremorine,
McN-A-343 and AF-102B.
The hypothesis of a presynaptic cholinergic mech-
anism for ALCAR is in agreement with previous results
demonstrating, by microdialysis studies, an increase in
ACh release from rat striatum and hippocampus induced
by ALCAR administration (Imperato et al., 1989). This
effect occurred in the same range of doses (50–200 mg
kg1 s.c.) in which the above-mentioned compound
exerted its antinociceptive activity. The increase of
extracellular ACh levels by ALCAR can arise from the
capability of this compound to be a precursor of ACh.
The synthesis of [14C]ACh from [14C]ALCAR was
observed in rat brain caudate nuclei slices (Dolezal and
Tucek, 1981) and in synaptosomal membrane prep-
aration from rat brain (White and Scates, 1990).
Other neurotransmission systems able to modulate
pain threshold are not involved in ALCAR antinocicep-
tion since the opioid antagonist naloxone, the GABAB
antagonist CGP-35348 and the monoamine synthesis
inhibitor (a)-methyl-p-tyrosine, were all unable to pre-
vent the effect of ALCAR. The doses and administration
schedules of the above-mentioned drugs were appropri-
ate for preventing antinociception induced respectively
by morphine (Ghelardini et al., 1992), the GABAB agon-
ist baclofen (Malcangio et al., 1991) and amphetamine
(Bartolini et al., 1987). Furthermore, pretreatment with
PTX did not prevent the analgesia induced by ALCAR.
It has been reported that PTX is able to antagonise the
analgesia induced by the most common analgesic drugs
such as morphine (Parenti et al., 1986), a2-adrenoceptor
agonists (Sanchez-Blazquez and Garzon, 1991), GABAB
agonists (Hoehn et al., 1988), tricyclic antidepressants
(Galeotti et al., 1996), with the exception of that induced
by cholinomimetic drugs (Galeotti et al., 1996). These
data further support the hypothesis not only of the lack
of involvement of non-cholinergic neurotransmitter sys-
tems, but also of the involvement of M1 receptors, which
are not coupled to Gi proteins, in the mechanism of anal-
gesic action of ALCAR.
Finally, we can exclude that the antinociceptive effect
of ALCAR is a consequence of an irreversible change in
afferent function since the increase of the pain threshold
induced by the investigated compound disappeared three
weeks after the end of the treatment. Moreover, the
observed reversion of the analgesia after treatment with
antimuscarinic compounds further indicates the lack of
induction of irreversible neuronal changes.
In summary, our results have shown that ALCAR is
able to produce antinociception in rodents after repeated
administration, without impairing motor coordination, by
potentiating endogenous cholinergic activity.
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